Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.
Virax Biolabs supports HHS's focus on vaccine efficacy transparency, offering technology to assess immune responses and collaborate with developers to improve vaccine research.
Virax Biolabs partners with Europa Biosite to distribute ImmuneSelect for research use, focusing on T-cell immunity and post-viral syndromes, including Long COVID.
Virax Biolabs stock is trading higher on Wednesday after the company announced it entered into a distribution agreement with a supplier of RT-PCR Mpox detection kits.
Virax Biolabs has signed a distribution agreement to commercialize RT PCR Mpox virus detection kits in Europe and Gulf countries, amid a WHO-declared international health emergency due to rising mpox cases.
Virax Biolabs shares are trading lower Thursday after the company announced a $5 million registered direct offering of ordinary shares. Here's a look at what's going on:
Virax Biolabs shares are racing higher Monday as shares of mpox-related stocks climb after the World Health Organization (WHO) declared the virus a global health emergency last week. Here's a look at what's going on:
